The Latest Breaking News from Alzheimer Disease

Disappointment after potential Alzheimer’s drug fails Roche trial

Swiss pharmaceutical firm carried out two identical phase 3 trials of gantenerumab, with about 1,000 volunteers in each

The Guardian - UK · Nov 14, 2022

Consumer Health: Can music help someone with Alzheimer's disease?

Alzheimer's disease is a progressive disorder that causes brain cells to waste away and die. Alzheimer's disease is the most common cause of dementia, which is a term used to describe a group of symptoms that affect memory, thinking and social abilities severely enough to interfere with daily function.

Tribune News Service · Nov 9, 2022

Does picking your nose really increase your risk of dementia?

Research Checks interrogate newly published studies and how they’re reported in the media. The analysis is undertaken by one or more academics not involved with the study, and reviewed by another, to make sure it’s accurate.

The Conversation · Nov 3, 2022

New Alzheimer's drug that slows cognitive decline could be available next year

People who are prescribed the drug will need regular MRI scans to check for brain swelling or bleeding

Wales Online · Oct 8, 2022

New Alzheimer's drug slows cognitive decline – and may be available as early as next year

Lecanemab is the first drug to help improve the symptoms of Alzheimer’s by slowing the disease. These are very promising results, although the only data we have at the moment is from the drugmaker’s press release.

The Conversation · Oct 4, 2022

Mayo Clinic expert offers perspective on experimental Alzheimer's disease drug

According to drugmakers Eisai and Biogen, a Phase 3 clinical study on a potential new Alzheimer's disease drug shows promise. The study findings show that the drug, lecanemab, reduced clinical decline of people with Alzheimer's disease by 27% compared with a placebo after 18 months of treatment.

Tribune News Service · Oct 4, 2022

Texas researchers receive $149 million for large study of Alzheimer’s in racial, ethnic groups

FORT WORTH, Texas — The National Institutes of Health is giving $149 million to researchers at the University of North Texas Health Science Center to pay for researchers to study the biology of Alzheimer’s disease in multiple racial and ethnic groups.

Tribune News Service · Oct 3, 2022

Alzheimer's risk increased by 80% in over 65s who have had Covid, claims study

Experts are still unclear as to whether Covid can trigger the onset of Alzheimer's or speed its development.

Daily Record · Oct 3, 2022

Over-65s twice as likely to develop Alzheimer’s within a year of Covid infection, according to study

Researchers from the Case Western Reserve University in Cleveland, Ohio analysed the electronic health records of 6.2 million adults

Evening Standard · Oct 3, 2022

Covid warning to everyone aged 66 and above

New research has found over 65s who contract covid increase their risk of getting Alzheimer's

Liverpool Echo · Oct 3, 2022